Skip to main content

Advertisement

SpringerLink
Log in

MRI after magnetic drug targeting in patients with advanced solid malignant tumors

  • Oncology
  • Published:
European Radiology Aims and scope Submit manuscript

Abstract

The purpose of this study was to evaluate the ability of MRI to detect magnetic particle uptake into advanced solid malignant tumors and to document the extension of these tumors, carried out in the context of magnetic drug targeting. In a prospective phase I trial, 11 patients were examined with MRI before and after magnetic drug targeting. The sequence protocol included T1-WI and T2-WI in several planes, followed by quantitative and qualitative evaluation of the signal intensities and tumor extensions. In nine patients, a signal decrease was observed in the early follow-up (2–7 days after therapy) on the T2-weighted images; two patients did not show a signal change. The signal changes in T1-WI were less distinct. In late follow-up (4–6 weeks after therapy), signal within nine tumors reached their initially normal level on both T1-WI and T2-WI; two tumors showed a slight signal decrease on T2-WI and a slight signal increase on T1-WI. Within the surveillance period, tumor remission in 3 out of 11 patients was observed, and in 5 patients tumor growth had stopped. The remaining three patients showed significant tumor growth. There was no statistically significant correlation between signal change and response. MRI is a suitable method to detect magnetite particles, deposited at the tumor site via magnetic drug targeting. MRI is therefore eligible to control the success of MDT and to assess the tumor size after the end of therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Alexiou C, Jurgons R, Schmid RJ, Bergemann C, Henke J, Erhardt W, Huenges E, Parak F (2003) Magnetic drug targeting—biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J Drug Target 11:139–149

    Article  CAS  PubMed  Google Scholar 

  2. Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW (2003) Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res 63:3154–3161

    CAS  PubMed  Google Scholar 

  3. Chen Y, Mcculloch RK, Gray BN (1994) Synthesis of albumin-Dextran sulfate microspheres possessing favourable loading and release characteristics for the anticancer drug Doxorubicin. J Control Release 31:49–54

    Article  CAS  Google Scholar 

  4. Lubbe AS, Bergemann C, Huhnt W, Fricke T, Riess H, Brock JW, Huhn D (1996) Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res 56:4694–4701

    CAS  PubMed  Google Scholar 

  5. Bonnemain B (1998) Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. A review. J Drug Target 6:167–174

    CAS  PubMed  Google Scholar 

  6. Kumano S, Murakami T, Kim T, Hori M, Okada A, Sugiura T, Noguchi Y, Kawata S, Tomoda K, Nakamura H (2003) Using superparamagnetic iron oxide-enhanced MRI to differentiate metastatic hepatic tumors and nonsolid benign lesions. Am J Roentgenol 181:1335–1339

    Google Scholar 

  7. Reimer P, Balzer T (2003) Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol 13:1266–1276

    PubMed  Google Scholar 

  8. Mack MG, Balzer JO, Straub R, Eichler K, Vogl TJ (2002) Superparamagnetic iron oxide-enhanced MR imaging of head and neck lymph nodes. Radiology 222:239–244

    PubMed  Google Scholar 

  9. Sigal R, Vogl T, Casselman J, Moulin G, Veillon F, Hermans R, Dubrulle F, Viala J, Bosq J, Mack M, Depondt M, Mattelaer C, Petit P, Champsaur P, Riehm S, Dadashitazehozi Y, de Jaegere T, Marchal G, Chevalier D, Lemaitre L, Kubiak C, Helmberger R, Halimi P (2002) Lymph node metastases from head and neck squamous cell carcinoma: MR imaging with ultrasmall superparamagnetic iron oxide particles (Sinerem MR)—results of a phase-III multicenter clinical trial. Eur Radiol 12:1104–1113

    Article  CAS  PubMed  Google Scholar 

  10. Bluemke DA, Weber TM, Rubin D, de Lange EE, Semelka R, Redvanly RD, Chezmar J, Outwater E, Carlos R, Saini S, Holland GA, Mammone JF, Brown JJ, Milestone B, Javitt MC, Jacobs P (2003) Hepatic MR imaging with ferumoxides: multicenter study of safety and effectiveness of direct injection protocol. Radiology 228:457–464

    PubMed  Google Scholar 

  11. Lee JM, Kim CS, Youk JH, Lee MS (2003) Characterization of focal liver lesions with superparamagnetic iron oxide-enhanced MR imaging: value of distributional phase T1-weighted imaging. Korean J Radiol 4:9–18

    PubMed  Google Scholar 

  12. Elmi MM, Sarbolouki MN (2001) A simple method for preparation of immuno-magnetic liposomes. Int J Pharm 215:45–50

    Article  CAS  PubMed  Google Scholar 

  13. Alexiou C, Arnold W, Klein R, Parak F, Hulin P, Bergemann C, Erhardt W, Wagenpfeil S, Lubbe A (2002) Locoregional cancer treatment with magnetic drug targeting. Cancer Res 60:6641–6648

    Google Scholar 

  14. Lubbe AS, Alexiou C, Bergemann C (2001) Clinical applications of magnetic drug targeting. J Surg Res 95:200–206

    Article  CAS  PubMed  Google Scholar 

  15. Montet X, Lazeyras F, Howarth N, Mentha G, Rubbia-Brandt L, Becker CD, Vallee JP, Terrier F (2004) Specificity of SPIO particles for characterization of liver hemangiomas using MRI. Abdom Imaging 29:60–70

    CAS  PubMed  Google Scholar 

  16. Couvreur P, Kante B, Lenaerts V, Scailteur V, Roland M, Speiser P (1980) Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles. J Pharm Sci 69:199–202

    CAS  PubMed  Google Scholar 

  17. Weissleder R, Bogdanov A, Neuwelt EA, Papisov M (1995) Longcirculating iron oxides for MR imaging. Adv Drug Deliv Rev 16:321–334

    Article  CAS  Google Scholar 

  18. Schutt W, Gruttner C, Hafeli U, Zborowski M, Teller J, Putzar H, Schumichen C (1997) Applications of magnetic targeting in diagnosis and therapy—possibilities and limitations: a mini-review. Hybridoma 16:109–117

    CAS  PubMed  Google Scholar 

  19. Brigger I, Dubernet C, Couvreur P (2002) Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54:631–651

    Article  CAS  PubMed  Google Scholar 

  20. Wang YX, Hussain SM, Krestin GP (2001) Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 11:2319–2331

    Article  CAS  PubMed  Google Scholar 

  21. Reimer P, Tombach B (1998) Hepatic MRI with SPIO: detection and characterization of focal liver lesions. Eur Radiol 8:1198–1204

    Article  CAS  PubMed  Google Scholar 

  22. Schima W (2002) Organ specific MRI contrast media in general practice. Wien Med Wochenschr (Suppl) 113:8–11

    PubMed  Google Scholar 

  23. Jordan A, Wust P, Scholz R, Tesche B, Fahling H, Mitrovics T, Vogl T, Cervos-Navarro J, Felix R (1996) Cellular uptake of magnetic fluid particles and their effects on human adenocarcinoma cells exposed to AC magnetic fields in vitro. Int J Hyperthermia 12:705–722

    CAS  PubMed  Google Scholar 

  24. Jordan A, Scholz R, Wust P, Fahling H, Krause J, Wlodarczyk W, Sander B, Vogl T, Felix R (1997) Effects of magnetic fluid hyperthermia (MFH) on C3H mammary carcinoma in vivo. Int J Hyperthermia 13:587–605

    CAS  PubMed  Google Scholar 

  25. Thomassen T, Wiggen UN, Gundersen HG, Fahlvik AK, Aune O, Klaveness J (1991) Structure activity relationship of magnetic particles as MR contrast agents. Magn Reson Imaging 9:255–258

    Article  CAS  PubMed  Google Scholar 

  26. Babincova M, Babinec P, Bergemann C (2001) High-gradient magnetic capture of ferrofluids: implications for drug targeting and tumor embolization. Z Naturforsch [C] 56:909–911

    CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by the Graduiertenkolleg GRK 331 “Temperaturabhängige Effekte in Therapie und Diagnostik” of the German Research Foundation [Deutsche Forschungsgemeinschaft (DFG)].

Author information

Authors and Affiliations

  1. Universitätsklinikum Charité, Campus Virchow-Klinikum, Medizinische Fakultät der Humboldt-Universität zu Berlin, Klinik für Strahlenheilkunde, Berlin, Germany

    A.-J. Lemke, M.-I. Senfft von Pilsach & R. Felix

  2. Cecilien-Klinik, Bad Lippspringe, Germany

    A. Lübbe

  3. Chemicell GmbH, Berlin, Germany

    C. Bergemann

  4. Universitätsklinikum Charité, Campus Virchow-Klinikum, Medizinische Fakultät der Humboldt-Universität zu Berlin, Medizinische Klinik, Schwerpunkt Hämatologie und Onkologie, Berlin, Germany

    H. Riess

Authors
  1. A.-J. Lemke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M.-I. Senfft von Pilsach
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Lübbe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Bergemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Riess
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Felix
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A.-J. Lemke.

Additional information

The used data are part of the thesis of M.-I. Senfft von Pilsach.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lemke, AJ., Senfft von Pilsach, MI., Lübbe, A. et al. MRI after magnetic drug targeting in patients with advanced solid malignant tumors. Eur Radiol 14, 1949–1955 (2004). https://doi.org/10.1007/s00330-004-2445-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00330-004-2445-7

Keywords

Search

Navigation